TBC
TBC
Validation Strategies for Pharmaceutical Patents in Europe
Special Report
The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries. The choice typically factors in costs, business interests, likely markets and market size, possible manufacturing and import locations and the regulatory framework in Europe.
This report explores these choices and factors using publicly available data, seeking to answer questions such as:
- Which countries are most commonly picked by patent holders at the EPO?
- Is the distribution the same for pharmaceutical patents?
- Where does “big pharma” choose to validate?
- What factors might affect the choice of countries?
Read our blogs
UPC Weekly - Purpose-based interpretation avoids infringement of medical device claim but defendant still on the hook for costs
2026 Week 3 Being sued for patent infringement at the UPC is a full-on experience. The front-loading of the procedure and the urgent time limits mean that far-reaching strategic decisions need to be ...
Front loading and pointers to the solution – the view from the UPC Court of Appeal
2026 Week 2 After the Edwards and Amgen decisions in late November 2025, we now have a further UPC Court of Appeal (CoA) decision, reviewing the outcome of first instance revocation proceedings at ...
.png)
The UPC going into 2026 – three key takeaways
2026 Week 1 2025 was a seriously busy year for the UPC. We came into the year with one case management system and we left it with a shiny new one. We go into 2026 with a new court fee schedule. In ...
-Dec-29-2025-09-11-25-2361-AM.png)
Careful with that saisie application
2025 Week 52 They can be conveniently bundled together informally as “provisional measures” at the UPC. But orders for preserving evidence (saisie orders) and preliminary injunctions are different in ...
When success does not mean survival – Generics knock out Sanofi’s cancer drug patent at the UPC
2025 Week 51 Generic pharmaceutical companies scored their first big win at the UPC last week, with the Munich Local Division (LD) revoking Sanofi’s patent EP 2493466 B1 for a medical use of the ...
The Vaginal Microbiome – the hidden key to success in IVF?
In vitro fertilisation (IVF) as the names suggests, is a fertility treatment where an egg is fertilised by a sperm outside of the body. For many couples diagnosed with infertility, IVF offers hope of ...
Mewburn Ellis
FORWARD MAGAZINE
Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.